In vitro comparison of biofilm formation and acidogenicity between human breast milk and other milk formulas

2020 ◽  
Vol 30 (2) ◽  
pp. 57-63
Author(s):  
Sanpob Trongsilsat ◽  
Jinthana Lapirattanakul ◽  
Rudee Surarit ◽  
Apiwan Smutkeeree
Keyword(s):  
Breast Milk ◽  
Biofilm Formation ◽  
Human Breast Milk ◽  
Human Breast ◽  
In Vitro Comparison

Safety and efficacy of human breast milk Lactobacillus fermentum CECT 5716. A mini-review of studies with infant formulae

2015 ◽  
Vol 6 (2) ◽  
pp. 219-224 ◽  
Author(s):  
E. López-Huertas
Keyword(s):  
Breast Milk ◽  
Probiotic Strain ◽  
Lactobacillus Fermentum ◽  
Controlled Trials ◽  
Human Breast Milk ◽  
Probiotic Properties ◽  
Human Breast ◽  
Safety And Efficacy

Human breast milk has been described as a source of lactic acid bacteria. Lactobacillus fermentum CECT5716 is a human breast milk strain whose probiotic properties, safety and efficacy has been demonstrated in vitro and in vivo, including controlled trials with human adults. Since the origin of this probiotic strain is human breast milk, we aimed to investigate the safety and efficacy of an infant and a follow-on formulas supplemented with this strain of L. fermentum. We carried out two randomised controlled trials: one trial with infants of 6-12 months of age (follow-on formula study) and another one with infants from 1 to 5 months of age (infant formula study). The results from the trials showed that the probiotic formulas were safe, well tolerated and might be useful for the prevention of community-acquired infections.

Effect of Human Milk and its Components on Streptococcus Mutans Biofilm Formation

2015 ◽  
Vol 39 (3) ◽  
pp. 255-261 ◽  
Author(s):  
LM Allison ◽  
LA Walker ◽  
BJ Sanders ◽  
Z Yang ◽  
G Eckert ◽  
...  
Keyword(s):  
Breast Milk ◽  
Streptococcus Mutans ◽  
Biofilm Formation ◽  
Current Knowledge ◽  
Post Partum ◽  
Human Breast Milk ◽  
Human Breast ◽  
Flat Bottom ◽  
Biofilm Growth ◽  
Microtiter Plates

Objective: This study investigated the effects of human breast milk and its components on the nutritional aspect of the caries process due to Streptococcus mutans UA159 biofilm formation. Study design: Human breast milk was collected from 11 mothers during 3-9 months postpartum. To test for the effect on biofilm formation, a 16-hour culture of S. mutans was treated with dilutions of human breast milk and several major components of human breast milk, lactose, lactoferrin, IgA, and bovine casein in sterile 96-well flat bottom microtiter plates for 24 hours. The biofilms were fixed, washed, stained with crystal violet, and extracted. Absorbance was measured to evaluate biofilm growth mass. Results: Dilutions 1:10-1:2,560 of the human breast milk samples increased biofilm formation by 1.5-3.8 fold compared to the control. Lactoferrin decreased biofilm formation significantly in all dilutions (average milk concentration of 3 mg/ml). Lactose had no effect at average breast milk concentrations (60 mg/ml) except at its lowest concentration (15 mg/ml) where it was increased. IgA significantly decreased biofilm formation at its highest concentration of 2,400 μg/ml (average milk concentration 600 μg/ml). Casein caused significantly increased biofilm formation at all concentrations tested above the average milk content (2.3 mg/ml). Conclusions: The results of this study demonstrate an increase in S. mutans biofilm formation by human breast milk 3-9 months post partum. Among its major components, only casein significantly increased biofilm formation among the concentrations analyzed. Lactose had no effect except at 15 mg/ml. Lactoferrin and IgA significantly decreased S. mutans biofilm formation at their highest concentrations. This information expands the current knowledge regarding the nutritional influence of breastfeeding and validates the necessity to begin an oral hygiene regimen once the first tooth erupts.

scholarly journals Analysis of Susceptibility to the Antimicrobial and Anti-Biofilm Activity of Human Milk Lactoferrin in Clinical Strains of Streptococcus agalactiae With Diverse Capsular and Sequence Types

2021 ◽  
Vol 11 ◽  
Author(s):  
Jacky Lu ◽  
Miriam A. Guevara ◽  
Jamisha D. Francis ◽  
Sabrina K. Spicer ◽  
Rebecca E. Moore ◽  
...  
Keyword(s):  
Breast Milk ◽  
Bacterial Growth ◽  
Neonatal Sepsis ◽  
Biofilm Formation ◽  
Late Pregnancy ◽  
Human Breast Milk ◽  
Human Breast ◽  
Wide Range ◽  
Group B ◽  
Sequence Types

Group B Streptococcus (GBS) is one of the leading infection-related causes of adverse maternal and neonatal outcomes. This includes chorioamnionitis, which leads to preterm ruptures of membranes and can ultimately result in preterm or stillbirth. Infection can also lead to maternal and neonatal sepsis that may contribute to mortality. Currently, treatment for GBS infection include a bolus of intrapartum antibiotic prophylaxis to mothers testing positive for GBS colonization during late pregnancy. Lactoferrin is an antimicrobial peptide expressed in human breast milk, mucosal epithelia, and secondary granules of neutrophils. We previously demonstrated that lactoferrin possesses antimicrobial and antibiofilm properties against several strains of GBS. This is largely due to the ability of lactoferrin to bind and sequester iron. We expanded upon that study by assessing the effects of purified human breast milk lactoferrin against a panel of phenotypically and genetically diverse isolates of GBS. Of the 25 GBS isolates screened, lactoferrin reduced bacterial growth in 14 and biofilm formation in 21 strains. Stratifying the data, we observed that colonizing strains were more susceptible to the growth inhibition activity of lactoferrin than invasive isolates at lactoferrin concentrations between 250-750 µg/mL. Treatment with 750 µg/mL of lactoferrin resulted in differences in bacterial growth and biofilm formation between discrete sequence types. Differences in bacterial growth were also observed between capsular serotypes 1a and III. Maternally isolated strains were more susceptible to lactoferrin with respect to bacterial growth, but not biofilm formation, compared to neonatal sepsis isolates. Finally, high biofilm forming GBS strains were more impacted by lactoferrin across all isolates tested. Taken together, this study demonstrates that lactoferrin possesses antimicrobial and antibiofilm properties against a wide range of GBS isolates, with maternally isolated colonizing strains being the most susceptible.

scholarly journals 2586. Human Breast Milk Inhibits the Replication of Parechovirus-A3

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S899-S899
Author(s):  
Ryohei Izumita ◽  
Kazuki Kon ◽  
Yuta Aizawa ◽  
Kanako Watanabe ◽  
Akihiko Saitoh
Keyword(s):  
Breast Milk ◽  
Neutralizing Antibody ◽  
Antiviral Effect ◽  
Vero Cells ◽  
Human Breast Milk ◽  
Strong Positive Correlation ◽  
Human Breast ◽  
Mature Milk ◽  
Young Infants

Abstract Background Parechovirus-A3 (PeV-A3) is an emerging pathogen causing sepsis and meningoencephalitis in neonates and young infants. We previously reported that maternal antibodies against PeV-A3 are important to protect neonates and young infants from the infection. Recent studies showed that (1) breastfeeding had a protective effect against enterovirus, which is closely-related virus to PeV-A, and (2) human breast milk (HBM) neutralized enterovirus in vitro. Currently, no report is available related to the antiviral effect of HBM against PeV-A3. Methods HBM (colostrum, 3–5 days after childbirth; mature milk, 1 month after childbirth) and serum (within ± 1 week of child’s birthday) samples were obtained from mothers at obstetrics clinic in Niigata, Japan. Neutralizing antibody titers (NATs) against PeV-A3 were measured using the Vero cells. Results The anti-PeV-A3 NATs of colostrum (n = 32) ranged from 1:8 to 1:2048, those ≥1:32 was 59% (19/32). Whereas, the anti-PeV-A3 NATs of mature milk ranged from 1:8 to 1:96. and those ≥1:32 was 20% (2/20) (P < 0.001). The median NATs anti-PeV-A3 was higher in colostrum (1:32) compared with mature milk (1:8) (P < 0.001). There was a strong positive correlation between the NATs of colostrum and serum (r = 0.604, P < 0.001, Figure). Conclusion This study showed that HBM had high NATs against PeV-A3, which was correlated with serum NATs. Further studies are necessary to investigate which components of HBM has antiviral effects against PeV-A3. Disclosures All authors: No reported disclosures.

Sign in / Sign up

Export Citation Format

Share Document